Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy
Propose Human epidermal growth factor receptor 2 (HER2) is overexpressed on the surface of some kinds of cancer cells including breast cancer. In this study, we designed and produced a novel immunotoxin consisting anti-HER2 single-chain Fv (scFv) from pertuzumab and a modified form of Pseudomonas exotoxin (PE35KDEL). Methods The three-dimensional (3D) structure of the fusion protein (anti-HER IT) was predicted by MODELLER 9.23 and its interaction with HER2 receptor was assessed using HADDOCK web server. Anti-HER2 IT, anti-HER2 scFv, and PE35KDEL proteins were expressed by Escherichia coli BL21 (DE3). After purification of the proteins using $ Ni^{2+} $ affinity chromatography and refolding through dialysis, the cytotoxicity of proteins against breast cancer cell lines was examined by MTT assay. Results In-silico studies showed that (EAAAK)2 linker can efficiently prevent the formation of salt bridges between two functional domains and the constructed fusion protein has a high affinity to HER2 receptor. The optimum condition of anti-HER2 IT expression was 25 °C and 1 mM IPTG. The protein was successfully purified and refolded by dialysis with a final yield of 45.7 mg per 1 L of bacterial culture. The cytotoxicity results showed that anti-HER2 IT was much more toxic on HER2-overexpressing cells, BT-474 ($ IC_{50} $ ~ 95 nM) compared with HER2-negative cells, MDA-MB-23 ($ IC_{50} $ ˃ 200 nM). Conclusion This novel immunotoxin has the potential to be applied as a therapeutic candidate for HER2-targeted cancer therapy. However further in vitro and in vivo evaluations are still required to confirm the efficacy and safety of this protein..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Biotechnology letters - 45(2023), 4 vom: 20. Feb., Seite 537-550 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shariaty Vaziri, Zahra [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10529-023-03360-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049817817 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049817817 | ||
| 003 | DE-627 | ||
| 005 | 20230325064716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230325s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10529-023-03360-4 |2 doi | |
| 035 | |a (DE-627)SPR049817817 | ||
| 035 | |a (SPR)s10529-023-03360-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shariaty Vaziri, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Propose Human epidermal growth factor receptor 2 (HER2) is overexpressed on the surface of some kinds of cancer cells including breast cancer. In this study, we designed and produced a novel immunotoxin consisting anti-HER2 single-chain Fv (scFv) from pertuzumab and a modified form of Pseudomonas exotoxin (PE35KDEL). Methods The three-dimensional (3D) structure of the fusion protein (anti-HER IT) was predicted by MODELLER 9.23 and its interaction with HER2 receptor was assessed using HADDOCK web server. Anti-HER2 IT, anti-HER2 scFv, and PE35KDEL proteins were expressed by Escherichia coli BL21 (DE3). After purification of the proteins using $ Ni^{2+} $ affinity chromatography and refolding through dialysis, the cytotoxicity of proteins against breast cancer cell lines was examined by MTT assay. Results In-silico studies showed that (EAAAK)2 linker can efficiently prevent the formation of salt bridges between two functional domains and the constructed fusion protein has a high affinity to HER2 receptor. The optimum condition of anti-HER2 IT expression was 25 °C and 1 mM IPTG. The protein was successfully purified and refolded by dialysis with a final yield of 45.7 mg per 1 L of bacterial culture. The cytotoxicity results showed that anti-HER2 IT was much more toxic on HER2-overexpressing cells, BT-474 ($ IC_{50} $ ~ 95 nM) compared with HER2-negative cells, MDA-MB-23 ($ IC_{50} $ ˃ 200 nM). Conclusion This novel immunotoxin has the potential to be applied as a therapeutic candidate for HER2-targeted cancer therapy. However further in vitro and in vivo evaluations are still required to confirm the efficacy and safety of this protein. | ||
| 650 | 4 | |a Immunotoxin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pseudomonas exotoxin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Human epidermal growth factor receptor 2 (HER2) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Breast cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Shafiee, Fatemeh |4 aut | |
| 700 | 1 | |a Akbari, Vajihe |0 (orcid)0000-0003-0754-1486 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biotechnology letters |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1979 |g 45(2023), 4 vom: 20. Feb., Seite 537-550 |w (DE-627)SPR010833447 |w (DE-600)2012203-2 |x 1573-6776 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:4 |g day:20 |g month:02 |g pages:537-550 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10529-023-03360-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 4 |b 20 |c 02 |h 537-550 | ||